The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab

For Immediate Release

Chicago, IL -December 20, 2018 - announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company LLY , Mitsubishi UFJ Financial Group, Inc. MUFG , Thermo Fisher Scientific Inc. TMO , Oracle ORCL and Ecolab ECL .

Here are highlights from Wednesday's Analyst Blog:

Top Analyst Reports for Lilly, Mitsubishi UFJ and Thermo Fisher

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, Mitsubishi UFJ Financial Group, Inc. and Thermo Fisher Scientific Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Buy-ranked Eli Lilly 's shares have gained +26.1% year to date, significantly outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +2.4% over the same period. Lilly's new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance, Lartruvo and Verzenio are expected to drive revenues.

The company expects to launch 20 new products by 2023, including at least two new indications/line extensions on average every year. Lilly is also having a strong year in terms of its pipeline with several positive late-stage data readouts and regulatory nods.

The newly launched CGRP antibody, Emgality could emerge as a significant contributor to long-term growth. It has also added promising new assets through business development deals. The stock has also outperformed the industry this year so far.

(You can read the full research report on Eli Lilly here >>> ).

Shares of Mitsubishi UFJ Financial have declined 12% in the last six months, underperforming the Zacks Foreign Banks industry which has declined 9.6% over the same period. Strong capital ratios and organic growth are likely to drive the company's bottom-line growth. Also, the company's prospects look encouraging, as it focuses on several strategies under its medium-term business plan and global expansion.

Nonetheless, the company's revenues continue to remain under pressure due to the negative interest rates in Japan. Also, rising costs due to strict regulations in overseas business remains a key concern.

(You can read the full research report on Mitsubishi UFJ here >>> ).

Shares of Buy-ranked Thermo Fisher have outperformed the Zacks Medical Instruments industry in the past three months (-5% vs. -15.1%). The company saw strength in all end markets categorized by customer type or geography in the last reported quarter. It particularly registered solid international performance with strong growth in Asia-Pacific including China. Also, a series of product launches with progress in precision medicine initiatives aided its performance.

The company's recently-closed acquisition of Advanced Bioprocessing business from BD should add complementary cell culture products to Thermo Fisher's bioproduction offerings. Also, the company's initiative to buy Gatan to boost electron microscopy suite buoys optimism.

(You can read the full research report on Thermo Fisher here >>> ).

Other noteworthy reports we are featuring today include Oracle and Ecolab.

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Ecolab Inc. (ECL): Free Stock Analysis Report

Oracle Corporation (ORCL): Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

Mitsubishi UFJ Financial Group, Inc. (MUFG): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More